MX2009006742A - Inhibidores acilaminopirazoles como fgfr. - Google Patents

Inhibidores acilaminopirazoles como fgfr.

Info

Publication number
MX2009006742A
MX2009006742A MX2009006742A MX2009006742A MX2009006742A MX 2009006742 A MX2009006742 A MX 2009006742A MX 2009006742 A MX2009006742 A MX 2009006742A MX 2009006742 A MX2009006742 A MX 2009006742A MX 2009006742 A MX2009006742 A MX 2009006742A
Authority
MX
Mexico
Prior art keywords
novel compounds
formula
compound
provided
medicament
Prior art date
Application number
MX2009006742A
Other languages
English (en)
Inventor
Andrew Peter Thomas
David Buttar
Kevin Michael Foote
Maria-Elena Theoclitou
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US87119006P priority Critical
Priority to US98554207P priority
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to PCT/GB2007/004917 priority patent/WO2008075068A2/en
Publication of MX2009006742A publication Critical patent/MX2009006742A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Abstract

Se proporciona un compuesto de Fórmula (I); o una sal farmacéuticamente aceptable del mismo. Así también proporciona un procedimiento para la preparación de un compuesto de Fórmula (I), y el uso de un compuesto de Fórmula (I) y como un medicamento y en el tratamiento del cáncer.
MX2009006742A 2006-12-21 2007-12-20 Inhibidores acilaminopirazoles como fgfr. MX2009006742A (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US87119006P true 2006-12-21 2006-12-21
US98554207P true 2007-11-05 2007-11-05
PCT/GB2007/004917 WO2008075068A2 (en) 2006-12-21 2007-12-20 Acylaminopyrazoles as fgfr inhibitors

Publications (1)

Publication Number Publication Date
MX2009006742A true MX2009006742A (es) 2009-08-24

Family

ID=39536793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006742A MX2009006742A (es) 2006-12-21 2007-12-20 Inhibidores acilaminopirazoles como fgfr.

Country Status (28)

Country Link
US (6) US7737149B2 (es)
EP (1) EP2125748B1 (es)
JP (1) JP5000726B2 (es)
KR (1) KR101467593B1 (es)
AR (1) AR064454A1 (es)
AT (1) AT510825T (es)
AU (1) AU2007336011B2 (es)
BR (1) BRPI0720551A2 (es)
CA (1) CA2672521C (es)
CO (1) CO6210721A2 (es)
CY (1) CY1111721T1 (es)
DK (1) DK2125748T3 (es)
EC (1) ECSP099436A (es)
HK (1) HK1139137A1 (es)
HR (1) HRP20110520T1 (es)
IL (1) IL199019A (es)
MX (1) MX2009006742A (es)
MY (1) MY146111A (es)
NO (1) NO342176B1 (es)
NZ (1) NZ577209A (es)
PE (1) PE15322008A1 (es)
PT (1) PT2125748E (es)
RU (1) RU2458920C2 (es)
SA (1) SA2481B1 (es)
SI (1) SI2125748T1 (es)
TW (1) TWI434846B (es)
UY (1) UY30819A1 (es)
WO (1) WO2008075068A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
WO2008078091A1 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
EP2195293B1 (en) 2007-08-22 2013-10-16 AstraZeneca AB Cycloptopyl amide derivatives
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
JP2011524888A (ja) * 2008-06-19 2011-09-08 アストラゼネカ アクチボラグ ピラゾール化合物436
BRPI0923480A2 (pt) 2008-12-22 2016-08-09 Merck Patent Gmbh formas polimorficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona e processos de fabricacao das mesmas
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
JO2860B1 (en) * 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Vinyl indazolyl compounds
JP2013520413A (ja) * 2010-02-18 2013-06-06 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag シクロプロピルアミド誘導体及びそれに関連する中間体の製造方法
CN103096893B (zh) 2010-06-04 2016-05-04 阿尔巴尼分子研究公司 甘氨酸转运体-1抑制剂、其制备方法及其用途
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9255072B2 (en) 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
JP5343177B1 (ja) 2012-02-28 2013-11-13 アステラス製薬株式会社 含窒素芳香族へテロ環化合物
KR20140140070A (ko) 2012-03-08 2014-12-08 아스테라스 세이야쿠 가부시키가이샤 신규 fgfr3 융합체
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Tlr阻害作用を有するチオフェン誘導体
PL3176170T3 (pl) 2012-06-13 2019-05-31 Incyte Holdings Corporation Podstawione związki tricykliczne jako inhibitory fgfr
WO2014002922A1 (ja) * 2012-06-26 2014-01-03 アステラス製薬株式会社 抗癌剤の併用による癌治療方法
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US20140179712A1 (en) * 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
PL403149A1 (en) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna New pirazolilobenzo[d]imidazole derivatives
EA201591420A1 (ru) 2013-03-15 2016-02-29 Селджен Авиломикс Рисерч, Инк. Гетероарильные соединения и их применение
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR20150129847A (ko) 2013-03-15 2015-11-20 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 융합 단백질 및 이들의 방법
IL240605D0 (en) 2013-03-15 2015-09-24 Sanofi Sa Heteroaryl compounds and uses thereof
HUE036571T2 (hu) 2013-04-19 2018-07-30 Incyte Holdings Corp Biciklusos heterociklusok mint FGFR inhibitorok
AR096393A1 (es) * 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
CN105792844A (zh) 2013-10-08 2016-07-20 第三共株式会社 抗fgfr2抗体和另一药剂的组合
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
BR112017002268A2 (pt) 2014-08-18 2017-11-21 Eisai R&D Man Co Ltd sal de derivado de piridina monocíclica e cristal do mesmo
CA2958503A1 (en) * 2014-08-19 2016-02-25 Shanghai Haihe Pharmaceutical Co., Ltd. Indazole compounds as fgfr kinase inhibitor, preparation and use thereof
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PE15142017A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN107406431A (zh) 2015-08-20 2017-11-28 浙江海正药业股份有限公司 吲哚类衍生物及其制备方法和其在医药上的用途
AU2017295038A1 (en) 2016-07-15 2019-01-24 Centre Hospitalier Sainte Anne Paris 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB843940A (en) 1955-09-27 1960-08-10 Kodak Ltd Method of processing photographic silver halide emulsions containing colour couplers
BE667399A (es) 1964-07-30 1965-11-16
JPH0145617B2 (es) 1981-03-13 1989-10-04 Konishiroku Photo Ind
JPS63133152A (en) 1986-11-26 1988-06-04 Konica Corp Silver halide photographic sensitive material containing novel magenta coupler
JPH0467645A (en) 1990-07-09 1992-03-03 Nec Kyushu Ltd Burn-in device
JP2890065B2 (ja) 1990-11-10 1999-05-10 コニカ株式会社 ハロゲン化銀写真感光材料
JPH04184437A (en) 1990-11-20 1992-07-01 Fuji Photo Film Co Ltd Color image forming method and silver halide color photographic sensitive material
JPH04292322A (en) 1991-03-19 1992-10-16 Fujitsu Ltd Rack supply/discharge device
JPH0511414A (ja) 1991-07-02 1993-01-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
CZ290470B6 (cs) 1991-10-18 2002-07-17 Monsanto Technology Llc 5 či 6 členné aromáty jako fungicidy pro kontrolu stéblolamu rostlin, způsob kontroly a fungicidní směs k provedení tohoto způsobu
EP0586686A1 (en) 1992-03-26 1994-03-16 Dowelanco N-heterocyclic nitro anilines as fungicides
GEP20002224B (en) 1992-10-02 2000-06-10 Monsanto Co Fungicides for the Control of Take-All Disease of Plants
TW240217B (es) 1992-12-30 1995-02-11 Glaxo Group Ltd
JP3156026B2 (ja) 1993-12-27 2001-04-16 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
EP0788358B1 (en) 1994-11-10 2004-03-31 Millennium Pharmaceuticals, Inc. Use of pyrazole compounds for the treatment of glomerulonephritis, cancer, atherosclerosis or restenosis
WO1998028269A1 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
CA2302438A1 (en) 1997-05-19 1998-11-26 Sugen, Inc. Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
CN1117081C (zh) * 1997-12-22 2003-08-06 拜尔有限公司 用芳基取代或杂芳基取代的杂环脲抑制raf激酶
US6271237B1 (en) 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
JP3310226B2 (ja) 1998-10-16 2002-08-05 松下電器産業株式会社 音声合成方法および装置
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
BR9916930A (pt) * 1999-01-19 2001-10-30 Boehringer Ingelheim Pharma Compostos heterocìclicos aromáticos comoagentes antiinflamatórios
IL144826D0 (en) 1999-02-10 2002-06-30 Welfide Corp Amide compounds and pharmaceutical compositions containing the same
WO2000049001A2 (en) 1999-02-16 2000-08-24 E.I. Du Pont De Nemours And Company Phenoxy-, phenylthio-, phenylamino-, benzyloxy-, benzylthio- or benzylaminopyrimidine insectidices and acaricides
JP2003507329A (ja) 1999-08-12 2003-02-25 ファルマシア・アンド・アップジョン・カンパニー 3(5)−アミノ−ピラゾール誘導体、それらの製造方法および抗腫瘍薬としてのそれらの使用
CN1222520C (zh) 1999-08-13 2005-10-12 沃泰克斯药物股份有限公司 c-JUN N-末端激酶(JNK)和其它蛋白激酶的抑制剂
US6552008B1 (en) 1999-09-24 2003-04-22 Smithkline Beecham Corporation Thrombopoietin mimetics
CA2420363A1 (en) * 2000-08-31 2002-03-07 Pfizer Products Inc. Pyrazole derivatives and their use as protein kinase inhibitors
US20050209297A1 (en) 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
EP1319657A4 (en) 2000-09-22 2005-03-02 Nihon Nohyaku Co Ltd N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same
AT548031T (de) 2000-12-18 2012-03-15 Inst Med Molecular Design Inc Inhibitoren gegen die produktion und freisetzung entzündungfördernder zytokine
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
AU2002305260A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
CN100379410C (zh) 2002-06-05 2008-04-09 株式会社医药分子设计研究所 糖尿病治疗药
TW200407112A (en) 2002-06-05 2004-05-16 Inst Med Molecular Design Inc Immunity-related protein kinase inhibitors
EP1514544A4 (en) 2002-06-06 2009-01-07 Inst Med Molecular Design Inc Antiallergic
ES2246603B1 (es) 2002-07-03 2007-06-16 Consejo Sup. De Investig. Cientificas Procedimiento para la preparacion de esteres de hidroxitirosol, esteres obtenidos y utilizacion.
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 小野薬品工業株式会社 Ccr4アンタゴニストおよびその医薬用途
AU2003253686A1 (en) 2002-08-01 2004-02-23 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
JP4171881B2 (ja) 2002-08-09 2008-10-29 株式会社大塚製薬工場 Acat−1阻害剤
ES2349532T3 (es) 2003-02-06 2011-01-04 Bristol-Myers Squibb Company Compuestos basados en tiazolilo útiles como inhibidores de cinasa.
JP2004292322A (ja) 2003-03-25 2004-10-21 Fuji Photo Film Co Ltd 水溶性アミド連結体の製造方法
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
EP1618092B1 (en) 2003-05-01 2010-09-22 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
US7115359B2 (en) 2003-07-25 2006-10-03 Konica Minolta Medical & Graphic, Inc. Photothermographic material
UA84712C2 (en) 2003-08-21 2008-11-25 Оси Фармасьютикалз, Инк. N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
US7432271B2 (en) 2003-09-02 2008-10-07 Bristol-Myers Squibb Company Pyrazolyl inhibitors of 15-lipoxygenase
US20050267182A1 (en) 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
AT473967T (de) 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
DE602005020611D1 (de) 2004-04-28 2010-05-27 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
BRPI0614472A2 (pt) 2005-08-02 2011-03-29 Irm Llc compostos e composições como inibidores de proteìna quinase
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof

Also Published As

Publication number Publication date
US20170260143A1 (en) 2017-09-14
SI2125748T1 (sl) 2011-08-31
UY30819A1 (es) 2008-07-31
NO342176B1 (no) 2018-04-09
EP2125748B1 (en) 2011-05-25
CY1111721T1 (xx) 2015-10-07
RU2458920C2 (ru) 2012-08-20
WO2008075068A2 (en) 2008-06-26
IL199019D0 (en) 2010-02-17
US20140066455A1 (en) 2014-03-06
HRP20110520T1 (xx) 2011-08-31
AR064454A1 (es) 2009-04-01
ECSP099436A (es) 2009-07-31
PT2125748E (pt) 2011-07-20
TWI434846B (zh) 2014-04-21
BRPI0720551A2 (pt) 2019-03-12
DK2125748T3 (da) 2011-08-01
JP2010513444A (ja) 2010-04-30
IL199019A (en) 2014-06-30
CO6210721A2 (es) 2010-10-20
AU2007336011B2 (en) 2011-09-22
HK1139137A1 (en) 2012-01-06
US20100273811A1 (en) 2010-10-28
AT510825T (de) 2011-06-15
TW200831500A (en) 2008-08-01
NZ577209A (en) 2012-04-27
CA2672521C (en) 2015-03-17
PE15322008A1 (es) 2008-12-12
US7737149B2 (en) 2010-06-15
KR20090094026A (ko) 2009-09-02
EP2125748A2 (en) 2009-12-02
US20150299134A1 (en) 2015-10-22
US8604022B2 (en) 2013-12-10
KR101467593B1 (ko) 2014-12-01
AU2007336011A1 (en) 2008-06-26
NO20092033L (no) 2009-08-06
SA2481B1 (ar) 2010-09-29
JP5000726B2 (ja) 2012-08-15
CA2672521A1 (en) 2008-06-26
US10301267B2 (en) 2019-05-28
US20120129844A1 (en) 2012-05-24
RU2009127644A (ru) 2011-01-27
WO2008075068A3 (en) 2008-10-02
US20080153812A1 (en) 2008-06-26
US9688640B2 (en) 2017-06-27
US8129391B2 (en) 2012-03-06
MY146111A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
JO2282B1 (en) Oxazol derivatives
MXPA06005578A (es) Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
CA2635482A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
TW200804384A (en) Triazolopyrazine derivatives
GEP20125469B (en) Inhibitors of akt activity
TW200621762A (en) Novel compounds
MX2008012482A (es) Compuestos de indazol.
TW200804338A (en) New compounds
TW200806665A (en) Organic compounds
TW201125863A (en) Amino oxazine derivatives
NZ540456A (en) Pyrrolopyrimidine derivatives for treating hyperproliferative disorders such as cancer
NZ545450A (en) Phenoxiacetic acid derivatives
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
UA82395C2 (en) N-substituted benzimidazolyl c-kit inhibitors
MX2007001650A (es) Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
CY1119381T1 (el) Παραγωγα 2-μεθυλομορφολινο πυριδο-, πυραζο- και πυριμιδο-πυριμιδινησ ωσ αναστολεισ mtor
TW200500358A (en) Compounds
HK1120441A1 (en) Drugs for treatment of ovarian cancer
SG174809A1 (en) Macrocyclic compounds useful as inhibitors of hepatitis c virus
MX2010013110A (es) Inhibidores de fosfoinosituro-3 cinasa.
MX2007010818A (es) Gamma lactamas sustituidas como agentes terapeuticos.
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
CA2566160A1 (en) Pyrrolopyrimidine derivatives useful in cancer treatment
TW200829258A (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200800173A (en) Pharmaceutical composition for external use

Legal Events

Date Code Title Description
FG Grant or registration